Comments on ‘standard and reference‐based conditional mean imputation’: Regulators and trial statisticians be aware
Accurate frequentist performance of a method is desirable in confirmatory clinical trials, but is not sufficient on its own to justify the use of a missing data method. Reference‐based conditional mean imputation, with variance estimation justified solely by its frequentist performance, has the surp...
Gespeichert in:
Veröffentlicht in: | Pharmaceutical statistics : the journal of the pharmaceutical industry 2024-09, Vol.23 (5), p.598-603 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Accurate frequentist performance of a method is desirable in confirmatory clinical trials, but is not sufficient on its own to justify the use of a missing data method. Reference‐based conditional mean imputation, with variance estimation justified solely by its frequentist performance, has the surprising and undesirable property that the estimated variance becomes smaller the greater the number of missing observations; as explained under jump‐to‐reference it effectively forces the true treatment effect to be exactly zero for patients with missing data. |
---|---|
ISSN: | 1539-1604 1539-1612 1539-1612 |
DOI: | 10.1002/pst.2373 |